BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Schizophrenia readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Schizophrenia\, from 
 ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06482554-872@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06482554)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Schizophrenia.\nStudy: Lumat
 eperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
 \nEstimated primary completion: December 2026. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/lumateperone#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06482554
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03817502-803@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Cariprazine (Vraylar): Phase 3 readout est. (NCT03817502)
DESCRIPTION:Cariprazine (Vraylar)\, phase 3\, Schizophrenia.\nStudy: Effica
 cy and Safety of Cariprazine in the Treatment of Adolescent Participants (
 13 to 17 Years of Age) With Schizophrenia\nEstimated primary completion: 1
 5 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cari
 prazine-vraylar#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03817502
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185815-803@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cariprazine (Vraylar): Phase 1/2 readout est. (NCT07185815)
DESCRIPTION:Cariprazine (Vraylar)\, phase 1/2\, Major Depressive Disorder.\
 nStudy: Pharmacokinetics\, Safety\, Tolerability and Efficacy of a Subcuta
 neous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects
  Eligible for Treatment With Oral Cariprazine\nEstimated primary completio
 n: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 cariprazine-vraylar#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07185815
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07185815-9227@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Cariprazine long-acting injection (Mapi Pharma): Phase 1/2 readout 
 est. (NCT07185815)
DESCRIPTION:Cariprazine long-acting injection (Mapi Pharma)\, phase 1/2\, S
 chizophrenia.\nStudy: Pharmacokinetics\, Safety\, Tolerability and Efficac
 y of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depo
 t) in Subjects Eligible for Treatment With Oral Cariprazine\nEstimated pri
 mary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cariprazine-long-acting-injection-mapi-pharma#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07185815
URL:https://assetmemo.bio/drug/cariprazine-long-acting-injection-mapi-pharm
 a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07423546-712@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 1/2 readout est. (NCT
 07423546)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 1/2\, Schizophre
 nia.\nStudy: A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizo
 phrenia\nEstimated primary completion: 30 April 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07423546
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06821945-7608@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Olanzapine (Zyprexa): Phase 2 readout est. (NCT06821945)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 2\, Schizophrenia.\nStudy: A Clini
 cal Trial to Evaluate the Safety and Efficacy of Olanzapine Titration Sche
 dule in Patients With Schizophrenia\nEstimated primary completion: May 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/olanzapine-zyprexa
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT068
 21945
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07363577-840@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:LB-102 (methylated amisulpride): Phase 3 readout est. (NCT07363577)
DESCRIPTION:LB-102 (methylated amisulpride)\, phase 3\, Schizophrenia.\nStu
 dy: Study to Evaluate LB-102 for the Treatment of Adult Patients With Acut
 e Schizophrenia\nEstimated primary completion: June 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lb-102-methylated-amisulpride#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07363577
URL:https://assetmemo.bio/drug/lb-102-methylated-amisulpride#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07467993-9513@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270729
DTEND;VALUE=DATE:20270730
SUMMARY:GXV813: Phase 2 readout est. (NCT07467993)
DESCRIPTION:GXV813\, phase 2\, Schizophrenia.\nStudy: Study to Assess the S
 afety\, Tolerability\, and Treatment Response of GXV813 in Hospitalized Ad
 ults With Schizophrenia\nEstimated primary completion: 29 July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/gxv813#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07467993
URL:https://assetmemo.bio/drug/gxv813#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288333-9469@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:NBI-1117570: Phase 2 readout est. (NCT07288333)
DESCRIPTION:NBI-1117570\, phase 2\, Schizophrenia.\nStudy: Evaluation of NB
 I-1117570 in Inpatient Adults With Schizophrenia\nEstimated primary comple
 tion: August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nb
 i-1117570#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07288333
URL:https://assetmemo.bio/drug/nbi-1117570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07742280-666@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Brexpiprazole (Rexulti): Phase 2/3 readout est. (NCT07742280)
DESCRIPTION:Brexpiprazole (Rexulti)\, phase 2/3\, Schizophrenia.\nStudy: A 
 Study to Evaluate the Pharmacokinetics\, Safety and Tolerability of Brexpi
 prazole for Extended-Release Injection in Subjects With Schizophrenia\nEst
 imated primary completion: August 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/brexpiprazole-rexulti#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07742280
URL:https://assetmemo.bio/drug/brexpiprazole-rexulti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07722728-803@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Cariprazine (Vraylar): Phase 2/3 readout est. (NCT07722728)
DESCRIPTION:Cariprazine (Vraylar)\, phase 2/3\, Schizophrenia.\nStudy: A St
 udy to Investigate Pharmacokinetics\, Safety\, and Tolerability of B2227 E
 xtended-Release Injectable Suspension and Vraylar® in Participants With S
 chizophrenia\nEstimated primary completion: August 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07722728
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04987229-9210@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Olanzapine/samidorphan (Lybalvi): Phase 3 readout est. (NCT04987229
 )
DESCRIPTION:Olanzapine/samidorphan (Lybalvi)\, phase 3\, Schizophrenia.\nSt
 udy: Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects\nEs
 timated primary completion: September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/olanzapine-samidorphan-lybalvi#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT04987229
URL:https://assetmemo.bio/drug/olanzapine-samidorphan-lybalvi#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05325645-666@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Brexpiprazole (Rexulti): Phase 3 readout est. (NCT05325645)
DESCRIPTION:Brexpiprazole (Rexulti)\, phase 3\, Schizophrenia.\nStudy: Tria
 l of Brexpiprazole Once-weekly (QW) Formulation in Patients With Acute Sch
 izophrenia\nEstimated primary completion: September 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/brexpiprazole-rexulti#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05325645
URL:https://assetmemo.bio/drug/brexpiprazole-rexulti#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06963034-9196@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Direclidine: Phase 3 readout est. (NCT06963034)
DESCRIPTION:Direclidine\, phase 3\, Schizophrenia.\nStudy: NBI-1117568-SCZ3
 029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia\nEst
 imated primary completion: October 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/direclidine#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06963034
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07703956-9327@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:VV119: Phase 2 readout est. (NCT07703956)
DESCRIPTION:VV119\, phase 2\, Schizophrenia.\nStudy: Evaluating Safety and 
 Efficacy of VV119 in Acute Schizophrenia Adults\nEstimated primary complet
 ion: 31 October 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /vv119#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07703956
URL:https://assetmemo.bio/drug/vv119#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07410507-822@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Brenipatide: Phase 2 readout est. (NCT07410507)
DESCRIPTION:Brenipatide\, phase 2\, Schizophrenia.\nStudy: A Study of Breni
 patide in Adult Participants With Schizophrenia\nEstimated primary complet
 ion: November 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 renipatide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07410507
URL:https://assetmemo.bio/drug/brenipatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06961968-1732@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Iloperidone (Fanapt): Phase 3 readout est. (NCT06961968)
DESCRIPTION:Iloperidone (Fanapt)\, phase 3\, Schizophrenia.\nStudy: Randomi
 zed Withdrawal Study in Patients With Schizophrenia\nEstimated primary com
 pletion: November 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/iloperidone-fanapt#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06961968
URL:https://assetmemo.bio/drug/iloperidone-fanapt#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07105098-9196@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Direclidine: Phase 3 readout est. (NCT07105098)
DESCRIPTION:Direclidine\, phase 3\, Schizophrenia.\nStudy: NBI-1117568-SCZ3
 030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia\nEst
 imated primary completion: November 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/direclidine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07105098
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07565428-9264@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Roluperidone: Phase 3 readout est. (NCT07565428)
DESCRIPTION:Roluperidone\, phase 3\, Schizophrenia.\nStudy: Study to Evalua
 te Efficacy and Safety of Roluperidone in Adult Subjects With Negative Sym
 ptoms and Stable Positive Symptoms of Schizophrenia and to Evaluate the Re
 lapse Rate of Roluperidone and Antipsychotic Medications\nEstimated primar
 y completion: December 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/roluperidone#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07565428
URL:https://assetmemo.bio/drug/roluperidone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07396870-710@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:LY03020: Phase 2 readout est. (NCT07396870)
DESCRIPTION:LY03020\, phase 2\, Schizophrenia.\nStudy: A Phase 2 Study to E
 valuate the Efficacy and Safety of LY03020 in Acutely Psychotic Participan
 ts With Schizophrenia\nEstimated primary completion: 31 December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ly03020#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07396870
URL:https://assetmemo.bio/drug/ly03020#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07145918-705@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Emraclidine: Phase 2 readout est. (NCT07145918)
DESCRIPTION:Emraclidine\, phase 2\, Schizophrenia.\nStudy: A Study to Asses
 s Adverse Events\, Change in Disease Activity\, and How Oral Emraclidine M
 oves Through the Body in Adult Participants With Schizophrenia\nEstimated 
 primary completion: February 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/emraclidine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07145918
URL:https://assetmemo.bio/drug/emraclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225712-857@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Ulotaront: Phase 3 readout est. (NCT07225712)
DESCRIPTION:Ulotaront\, phase 3\, Schizophrenia.\nStudy: A Long-term Admini
 stration Trial of SEP-363856 in Patients With Schizophrenia\nEstimated pri
 mary completion: March 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/ulotaront#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07225712
URL:https://assetmemo.bio/drug/ulotaront#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07759869-9280@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:HS-10380: Phase 3 readout est. (NCT07759869)
DESCRIPTION:HS-10380\, phase 3\, Schizophrenia.\nStudy: A Study to Evaluate
  the Long-term Safety of HS-10380 in Patients With Schizophrenia\nEstimate
 d primary completion: 31 July 2028. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/hs-10380#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07759869
URL:https://assetmemo.bio/drug/hs-10380#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06882785-712@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20280923
DTEND;VALUE=DATE:20280924
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT06
 882785)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT in Acutely
  Psychotic Japanese Adult Participants With Schizophrenia\nEstimated prima
 ry completion: 23 September 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06882785
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07369154-840@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:LB-102 (methylated amisulpride): Phase 3 readout est. (NCT07369154)
DESCRIPTION:LB-102 (methylated amisulpride)\, phase 3\, Schizophrenia.\nStu
 dy: 52-week Open Label Safety-Tolerability Study\nEstimated primary comple
 tion: December 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 lb-102-methylated-amisulpride#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07369154
URL:https://assetmemo.bio/drug/lb-102-methylated-amisulpride#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07680946-6993@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20281212
DTEND;VALUE=DATE:20281213
SUMMARY:Briumvi (Ublituximab): Phase 2 readout est. (NCT07680946)
DESCRIPTION:Briumvi (Ublituximab)\, phase 2\, Schizophrenia.\nStudy: Study 
 to Evaluate the Safety and Efficacy of Ublituximab in Participants With Sc
 hizophrenia\nEstimated primary completion: 12 December 2028. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/ublituximab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07680946
URL:https://assetmemo.bio/drug/ublituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07911787-9280@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290124
DTEND;VALUE=DATE:20290125
SUMMARY:HS-10380: Phase 3 readout est. (NCT07911787)
DESCRIPTION:HS-10380\, phase 3\, Schizophrenia.\nStudy: Phase 3 Study of HS
 -10380 for Acute Schizophrenia in Chinese Adults\nEstimated primary comple
 tion: 24 January 2029. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/hs-10380#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07911787
URL:https://assetmemo.bio/drug/hs-10380#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07686263-712@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290303
DTEND;VALUE=DATE:20290304
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 686263)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: Relapse Prevention Trial Evaluating KarXT Treatment in Schizoph
 renia\nEstimated primary completion: 3 March 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07686263
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227818-9196@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Direclidine: Phase 3 readout est. (NCT07227818)
DESCRIPTION:Direclidine\, phase 3\, Schizophrenia.\nStudy: Efficacy of NBI-
 1117568 in Preventing Relapse in Adults With Schizophrenia\nEstimated prim
 ary completion: July 2029. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/direclidine#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07227818
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288567-712@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20291218
DTEND;VALUE=DATE:20291219
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 288567)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: A Study to Evaluate the Efficacy and Safety of KarXT for the Tr
 eatment of Schizophrenia in Adolescents (EMERGENT TEEN)\nEstimated primary
  completion: 18 December 2029. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/xanomeline-trospium-chloride#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07288567
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07459647-707@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Betovumeline/fesoterodine (ML-007C-MA): Phase 2 readout est. (NCT07
 459647)
DESCRIPTION:Betovumeline/fesoterodine (ML-007C-MA)\, phase 2\, Schizophreni
 a.\nStudy: A Long-Term Open-Label Study of ML-007C-MA in Adults With Schiz
 ophrenia\nEstimated primary completion: February 2030. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/betovumeline-fesoterodine-ml-007c-ma#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0745964
 7
URL:https://assetmemo.bio/drug/betovumeline-fesoterodine-ml-007c-ma#upcomin
 g-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07424404-712@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20300308
DTEND;VALUE=DATE:20300309
SUMMARY:Cobenfy (Xanomeline/trospium chloride): Phase 3 readout est. (NCT07
 424404)
DESCRIPTION:Cobenfy (Xanomeline/trospium chloride)\, phase 3\, Schizophreni
 a.\nStudy: A Study to Evaluate the Long-term Safety and Tolerability of Xa
 nomeline and Trospium Chloride for the Treatment of Psychiatric Disorders 
 in Children and Adolescents\nEstimated primary completion: 8 March 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/xanomeline-trospium-ch
 loride#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07424404
URL:https://assetmemo.bio/drug/xanomeline-trospium-chloride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07114874-9196@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Direclidine: Phase 3 readout est. (NCT07114874)
DESCRIPTION:Direclidine\, phase 3\, Schizophrenia.\nStudy: NBI-1117568-SCZ3
 032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia\nEst
 imated primary completion: December 2031. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/direclidine#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07114874
URL:https://assetmemo.bio/drug/direclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152184-7470@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20320201
DTEND;VALUE=DATE:20320202
SUMMARY:Quetiapine (Seroquel XR): Phase 2 readout est. (NCT07152184)
DESCRIPTION:Quetiapine (Seroquel XR)\, phase 2\, Schizophrenia.\nStudy: Stu
 dy Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Pat
 ients With Schizophrenia Spectrum Disorder: a Personalized Medicine Approa
 ch\nEstimated primary completion: 1 February 2032. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/quetiapine-seroquel-xr#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07152184
URL:https://assetmemo.bio/drug/quetiapine-seroquel-xr#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152184-7608@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20320201
DTEND;VALUE=DATE:20320202
SUMMARY:Olanzapine (Zyprexa): Phase 2 readout est. (NCT07152184)
DESCRIPTION:Olanzapine (Zyprexa)\, phase 2\, Schizophrenia.\nStudy: Study C
 omparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patient
 s With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach\n
 Estimated primary completion: 1 February 2032. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07152184
URL:https://assetmemo.bio/drug/olanzapine-zyprexa#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152184-9193@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20320201
DTEND;VALUE=DATE:20320202
SUMMARY:Risperidone (Risperdal): Phase 2 readout est. (NCT07152184)
DESCRIPTION:Risperidone (Risperdal)\, phase 2\, Schizophrenia.\nStudy: Stud
 y Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Pati
 ents With Schizophrenia Spectrum Disorder: a Personalized Medicine Approac
 h\nEstimated primary completion: 1 February 2032. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/risperidone-risperdal#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07152184
URL:https://assetmemo.bio/drug/risperidone-risperdal#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07152184-9231@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20320201
DTEND;VALUE=DATE:20320202
SUMMARY:Quetiapine (Seroquel): Phase 2 readout est. (NCT07152184)
DESCRIPTION:Quetiapine (Seroquel)\, phase 2\, Schizophrenia.\nStudy: Study 
 Comparing Antipsychotic Dose Reduction vs. Maintenance Treatment in Patien
 ts With Schizophrenia Spectrum Disorder: a Personalized Medicine Approach\
 nEstimated primary completion: 1 February 2032. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/quetiapine-seroquel#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07152184
URL:https://assetmemo.bio/drug/quetiapine-seroquel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06229210-872@assetmemo.bio
DTSTAMP:20261121T004011Z
DTSTART;VALUE=DATE:20320428
DTEND;VALUE=DATE:20320429
SUMMARY:Caplyta (Lumateperone): Phase 3 readout est. (NCT06229210)
DESCRIPTION:Caplyta (Lumateperone)\, phase 3\, Schizophrenia.\nStudy: Safet
 y and Tolerability Trial of Lumateperone in Pediatric Patients With Schizo
 phrenia\, Bipolar Disorder or Autism Spectrum Disorder\nEstimated primary 
 completion: 28 April 2032. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/lumateperone#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06229210
URL:https://assetmemo.bio/drug/lumateperone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
